Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

APL-101 and Osimertinib for the Treatment of EGFR-Mutated Metastatic Non-small Cell Lung Cancer

Trial Status: active

This phase I/II trial is to find out the best dose of APL-101 given together with osimertinib and the effect of APL-101 and osimertinib in treating patients with EGFR-mutated non-small cell lung cancer that has spread to other places in the body (metastatic). APL-101 and osimertinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving APL-101 together with osimertinib may work better than osimertinib alone in treating patients with non-small cell lung cancer.